Biocept BIOC Stock News

Biocept Inc (NASDAQ: BIOC)

Biocept is having an incredible day in the market today after announcing the launch of a new testing parameter. Biocept is involved in testing for various cancers without an intrusive tissue biopsy. Instead, the company focuses on liquid biopsies. Today, we’ll talk about the new testing parameter, what it means for BIOC, how the market is reacting to the news, and what we can expect to see moving forward.

Biocept Launches CLIA-validated Androgen Receptor Expression Assay

Biocept has launched several liquid biopsy tests over the past year, and it doesn’t seem as though the company’s innovation is going to come to an end any time soon. In fact, today it was announced that BIOC has launced the CLIA-validated androgen receptor expression assay, a test that uses the patient’s blood as a medium to detect and monitor late-stage prostate cancer as well as specific forms of breast cancer. The new test uses circulating tumor cells derived from a blood sample in an attempt to detect androgen receptor expression. This expression is overwhelmingly prevalent among patients that have advanced stage prostate cancer. Because prostate cancer is the second leading cause of male cancer-related death as well as the second most commonly diagnosed cancer in the United States, it is estimated that there will be incredibly high levels of demand for the new test. In a statement, Michael W. Nall, the President and CEO of BIOC had the following to say:

This test represents a significant milestone in which we expand into prostate cancer and further demonstrate the versatility of our proprietary liquid biopsy platforms… We continue to build on our leadership position in the emerging liquid biopsy field with commercialized tests for the detection and monitoring of lung, breast, colon, gastric and now prostate cancers.”

How BIOC Reacted To The News

As investors, we’ve come to expect that any time positive news is released with regard to a publicly traded company, we will see gains. That’s exactly what we’re seeing from BIOC today. Currently (11:10), the stock is trading at $1.58 per share after a gain of 18.87% so far today.

What The New Test Means For BIOC

This news is absolutely huge for Biocept. The company is in the process of revolutionizing the way cancer is diagnosed and treated. While revolutionary changes are never easy, Biocept seems to be very successful in reaching their goals. As mentioned by the CEO, BIOC has now added prostate cancer to their long list of cancers detectable through liquid biopsies. This further validates Biocept’s goal of creating a system of less intrusive and faster testing for those experiencing cancer-related symptoms.

What We Can Expect To See From BIOC Moving Forward

Moving forward, I have an overwhelmingly positive opinion of what we can expect to see from BIOC. The company has come up with several liquid biopsy tests, proving that their method of cancer detection is effective. They have also proven to be successful in the commercialization of these tests. All in all, the new prostate cancer test not only validates the company’s goal, but will likely lead to further gains for BIOC and its investors.

What Do You Think?

Where do you think BIOC is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Dynavax DVAX Stock News

Dynavax Technologies Corporation (NASDAQ: DVAX)

Dynavax is having an incredible day in the market after announcing the results of its most recent Phase 3 clinical trial. The trial met both co-primary endpoints. Today, we’ll talk about the results of the study, how the market reacted in the news, and what we can expect to see from DVAX moving forward.

DVAX Reports Preliminary Top-line Results

Early this morning, Dynavax Technologies reported preliminary top-line results with regard to the Phase 3 trial of an investigational vaccine for hepatitis B known as HEPLISAV-B. During the study, one group of patients was provided HEPLISAV-B in two doses, one at zero and one at one month. The other group of patients was provided Engerix-B in three doses, one at zero, one at one, and one at six months. During the study, the company was looking for a statistically significant higher rate of seroprotection than that provided by Engerix-B in both diabetic participants and in all participants in the group as well as proving that the vaccine had a strong safety profile. It has been announced that DVAX was able to meet both primary endpoints with the vaccine. In a statement, Eddie Gray, CEO at Dynavax Technologies had the following to say:

We are delighted to report these topline results from HBV-23 and confirm our intention to resubmit the HEPSLISAV-B BLA by the end of March. These results support our belief that HEPLISAV-B, if approved, could offer benefits to adults at risk for hepatitis B, particularly given that these significant differences in seroprotection were demonstrated in a controlled setting, where compliance is optimized…”

How DVAX Is Reacting To The News

Any time we see positive news with regard to a publicly traded company, we can expect to see gains in the value of that company’s stock. That’s exactly what we’re seeing from DVAX today. Currently (9:34), Dynavax Technologies is trading at $25.27 after a gain of 19.31% so far today.

When Will DVAX Be Submitting HEPLISAV-B To The FDA?

Now that Dynavax has met both of its co-primary endpoints on the Phase 3 trial, it only makes sense that the company will submit a Biologics License Application with the FDA. While the company has submitted a BLA on the drug in the past, the first submission was turned down as the FDA needed more data. However, following the recent study, DVAX should have all of the data that the FDA needs. As a result, we are expecting to see the company resubmit the BLA by the end of the first quarter of 2016. DVAX has already announced that it is anticipating a 6-month review period.

What We Can Expect To See Moving Forward

Moving forward, I have overwhelmingly positive expectations with regard to what we can expect to see from DVAX. While the company’s first BLA on HEPLISAV-B was denied, I believe that the most recent study shows that the vaccine meets all criteria to be approved. Therefore, I’m expecting the submission of the BLA to be a catalyst, followed by approval of HEPLISAV-B acting as another reason for investor excitement. All in all, things are looking up from here.

What Do You Think?

Where do you think DVAX is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Dynavax]

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD) | Sanofi SA (ADR) (NYSE: SNY)

MannKind is having an incredibly hard time in the market as of late. Yesterday, it was announced that the commercialization agreement between MannKind and Sanofi is coming to an end. However, as the story unfolds, it’s starting to become clear that MNKD is actually a victim of SNY and, if investors are smart, they will push the company to take Sanofi to court! Today, we’ll talk about why I believe MNKD is a SNY victim, the fact that this isn’t the first time this has happened, and why I believe it’s a good idea to get involved in MNKD.

Why MannKind Is A Victim Of Sanofi

Last year, after the approval of MannKind’s Afrezza, Sanofi was contracted for the commercialization of the treatment. Afrezza is an inhaled insulin that has the potential to create a pivotal change in the treatment of diabetes. Because Afrezza takes the need for an injection out of insulin treatment, Sanofi should have had a relatively easy time marketing the treatment. However, throughout the year 2015, SNY was dragging its feet with regard to the commercialization of the treatment. As a result, sales were overwhelmingly poor and MNKD suffered!

When it finally became time to start the direct to consumer phase, a phase that was expected to increase sales and improve MNKD stock prices, Sanofi fiddled with their responsibilities yet again. While SNY did place magazine and online ads, investors pushed for television ads to no avail! However, the reason Sanofi decided to delay with regard to Afrezza was a bit back-handed.

Sanofi is a company that is in charge of commercializing several treatments, one of which is known as Lantus. Lantus is an insulin in the more mainstream form. That’s right, it’s an insulin injection. So, naturally, SNY wouldn’t want the treatment MNKD came up with to become the standard of care. After all, if Afrezza became the standard of care, it would essentially affect the bottom line of Sanofi. While the ties between MNKD and SNY are in the process of breaking, I don’t think that this is enough. Throughout the time Sanofi was dragging its feet, the company was driving MannKind into the ground. Now, it’s time for them to pay the price. Eventually, MNKD should take Sanofi to court for their wrong doing during their relationship.

This Isn’t The First Time Sanofi Willfully Held Back On Commercialization

While it may come as a surprise to some, MNKD investors know that Sanofi has a history of dragging its feet when it comes to the commercialization of treatments. In fact, many believe that this is done on purpose to drive the competition down, and that belief really makes sense. In fact, Sanofi was recently taken to court for doing just that. On November 9th, a lawsuit was filed against Sanofi with regard to stalling the development of a multiple sclerosis drug known as Lemtrada. The suit claims that Sanofi delayed the commercialization of the drug in an attempt to avoid paying out at least $708 million to rights holders under its 2011 agreement to acquire Genzyme Corp.

What We Can Expect To See Moving Forward

First and foremost, MNKD investors should be pushing the company to take SNY to court for their wrongful delay of commercialization of Afrezza, costing MNKD and its investors millions of dollars! Outside of this issue, I believe that MannKind is going to climb in the future. Once a television ad is created, I believe that sales will climb in a big way! All in all, things don’t look good for the short term for MNKD. However, in the long term, the company has quite a bit going for it!

What Do You Think?

Do you think MannKind should take Sanofi to court? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Gilead Sciences GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences went through a bit of a roller coaster ride in 2015. However, 2016 looks like it’s going to pan out to be a very good year for the stock. After recent downtrends, GILD is trading at an incredible discount. Additionally, yesterday the company reported positive news with regard to its hepatitis B drug candidate. Today, we’ll talk about the news with regard to the hepatitis B candidate as well as other reasons that I believe that GILD is currently primed for picking!

Gilead Sciences Releases Positive Hepatitis B Data

On Tuesday, Gilead Sciences reported the results of two Phase 3 trials focused on a once-daily drug known as tenofovir alafenamide. Both of which proved to be overwhelmingly positive. In the studies, GILD proved that tenofovir alafenamide demonstrates better renal and bone safety than Viread, the company’s currently approved drug for treating this condition. As a result of the positive news, Gilead is planning its next step, which is to seek regulatory approval in both the United States and Europe. The company is expected to submit New Drug Applications to regulatory agencies in these regions during the first quarter of fiscal 2016. Considering that the new drug, tenofovir alafenamide, has been proven to be better than the currently approved drug, Viread, GILD should have no problem getting the new treatment approved.

Other Reasons That GILD Is A Strong Investment At The Moment

While the hepatitis B studies proved to be a hit, they are not the only reasons that investors should be excited about Gilead Sciences. In fact, there are several reasons for investors to get involved in this stock. To name a few:

  • New Hepatitis C Treatment – Gilead Sciences has been working on a new hepatitis C combination drug that’s likely to be better than anything out there, including the company’s own Harvoni. Recently, GILD announced that the United States Food and Drug Administration has granted the combination treatment a priority review. As a result, the FDA is hoping to announce whether or not the new treatment will be approved by June 28th.
  • Current Standing In The Hepatitis C Market – One of the reasons that Gilead Sciences had a bit of a rough year last year was due to the competition the company was facing in the hepatitis C market. Early in the year, AbbVie was approved for its own hepatitis C drug that came with a lower cost. However, AbbVie’s drug also came with horrible side effects and included a component that was known to be dangerous. As a result, GILD held its position as the leader in the treatment of the ailment.
  • GILD Is Trading At A Big Discount – Because of the recent downward movement we’ve seen on GILD, the stock is now trading at an incredible discount. In the biotechnology market, stocks are generally considered healthy when they trade at rates that are around 16 or 17 times earnings. However, Gilead is trading at a far better rate. In fact, investors can pick this stock up for less than 10 times earnings! This is an incredible discount for those that want to get in on the gains Gilead is likely to generate.

The Bottom Line

The bottom line here is that Gilead is an incredible company that’s known for meaningful innovation in the biotechnology space. The company has maintained control in the hepatitis C market, even though few thought they could. Now GILD is pushing two new treatments to the FDA and European health authorities for approval, which will likely lead to profits in the long run. With the stock trading at such an incredible discount, it’s hard to find a reason not to invest!

What Do You Think?

Where do you think GILD is headed moving forward and why? Let us know your opinion in the comments below!

[Image Courtesy of Flickr]

Valeant Pharmaceuticals VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant Pharmaceuticals has come across some hard times as of late. Between the claims of the company being the Enron of the pharmaceutical industry, investigations, and their relationship with a less than reputable pharmacy, the stock has fallen. Now, even more bad news has hit the company. The CEO, J. Michael Pearson, is incredibly ill. At first, we heard that Pearson was going on a leave of absence. Now, it seems as though things may get even more grim. Early this morning, it was announced that VRX had appointed an interim CEO. Today, we’ll talk about the health struggles that Pearson is facing, who the appointed interim CEO is, and what we can expect to see from VRX moving forward.

J. Michael Pearson Is Very Sick At The Moment

J. Michael Pearson, the CEO of Valeant Pharmaceuticals, has been in the hospital for some time now. While the family has requested that his condition remain private, we do know that he is suffering from a severe case of pneumonia and that he has been for quite some time. In fact, more than a week ago, VRX investors learned that Pearson was on a medical leave of absence. While the details of his condition are being held under wraps, it seems as though things are going from bad to worse. VRX announced today that they have appointed an interim CEO, insinuating that, at the very least, Pearson will be on an extended medical leave.

Valeant Appoints Howard B. Schiller As Interim CEO

Howard B. Schiller has now taken on the role as interim CEO at Valeant. While this may be a cause for concern for investors, Schiller is no newbie when it comes to running a company the size of VRX. In fact, he has been the CEO at Valeant in the past. From December 2011 through June of 2015, Schiller acted as the CEO of the massive pharmaceutical company. Even after his stint as CEO of the company, Howard B. Schiller served on the company’s Board of Directors. In a statement, Robert Ingram, Lead Independent Director and interim chairman of the Board of Directors, had the following to say:

As Mike’s medical leave continues, and the timing of his recovery and return remains uncertain, Howard will now step in as CEO on an interim basis. Howard’s performance as Valeant’s CFO, as well as deep understanding of Valeant’s operations, are excellent and we are grateful that he has agreed to take on this role. The Board will continue to work closely with Howard and the other members of the senior management team to implement Valeant’s strategy successfully in Mike’s absence.

We appreciate the expressions of support and concern for Mike’s health that we have received from Valeant’s investors, employees, business partners and other stakeholders. While Mike’s illness was sudden and unexpected, our strong management team has stepped in to keep our businesses on track and thriving. We particularly appreciate the leadership of Rob Chai-Onn, Ari Kellen and Rob Rosiello at this important time.”

What We Can Expect To See Moving Forward

First and foremost, today isn’t likely to be a strong day for VRX. Unfortunately, when bad news is produced with regard to a company, we tend to see a negative reaction in the market. However, the declines we’re likely to see in the short run can be considered a door opening to opportunity. The reality is that VRX has bounced back from recent struggles in a big way. They have gotten the press under control and even signed an agreement with Walgreens that is likely to increase their sales. All in all, things are looking great for the long term outlook at Valeant Pharmaceuticals.

What Do You Think?

Where do you think VRX is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

MannKind has had a rough time in the market over the past year, and that hard time has been exacerbated today. Earlier today, the company announced the termination of their license agreement with Sanofi SA (ADR) (NYSE: SNY). As a result, the stock is sinking. However, in the long run outlook, termination of the relationship with Sanofi isn’t necessarily a bad thing for MannKind. Today, we’ll talk about the termination of the agreement, why this isn’t necessarily a bad thing, and what we can expect to see from MNKD moving forward.

MannKind Terminates Relationship With Sanofi

As mentioned above, MannKind has had a rough time in the market as of late. However, quite a bit of the struggles the company has been facing are the result of their relationship with Sanofi. MNKD created an inhaled insulin that is known as Afrezza, then licensed commercialization to SNY. Unfortunately however, marketing efforts by Sanofi simply haven’t been positive. In fact, MannKind’s stock has been sinking because Afrezza sales just don’t seem to be picking up. As a result, MNKD made the decision to terminate the agreement they had with SNY. The termination of the agreement will be effective no later than July 4th, 2016.

How The Market Is Reacting To The News

Unfortunately, the reaction that we’re seeing today in the market is anything but positive. At the moment (10:10), MNKD is trading at $1.00 per share after a loss of 30.69% so far today.

This Isn’t Really Bad News!

If you judge the news based on the market reaction, you would think that the termination of the agreement between MNKD and SNY is a bad thing. However, in my opinion, this is actually a positive move. The reality is that Sanofi’s role in the agreement was to market Afrezza in a way that would be profitable. Unfortunately, due to a conflict of interest, Sanofi simply hasn’t put forth the efforts they should have in this partnership. As a result, Afrezza sales have suffered and MNKD has fallen dramatically in the market over the past several months.

Nonetheless, MNKD is a great company with a great product. They know that Afrezza is an overwhelmingly positive thing that has the potential to revolutionize the way we view the treatment of diabetes, and they know that commercialization can be much better. So, at this point, MannKind is going to be looking into different strategies that will give Afrezza the lime light it deserves… Sanofi simply isn’t making the cut!

What We Can Expect To See Moving Forward

After today’s dramatic decline, MNKD is trading at an incredibly low price. In my opinion, this creates opportunity. The reality is that Afrezza is a great treatment that is needed by a large percentage of the diabetic population. Without Sanofi, MannKind can focus on commercialization on their own. In all honesty, all it would likely take is a television advertisement to see sales climb in a big way. I believe that MannKind knows this and that the reason they terminated the agreement with Sanofi is so that they can do a better job. As a result, I’m expecting choppy movement over the next few months followed by solid gains in the long run!

What Do You Think?

Where do you think MNKD is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Biotech Stock News

Kalobios (NASDAQ:KBIO)

On Tuesday December 29, 2015 Kalobios made an SEC filing whereby the company filed for Chapter 11 Bankruptcy. This does not mean that the company is going bankrupt, instead it signifies that the company needs to put its functions on hold until it can develop a proper restructuring plan. This filing occurred in the Court of Delaware, which is the state the company presides in. This desperately needed to be done, because the company was unsuccessful at its first restructure attempt while operations were continuing. For instance, the company attempted to do an out of court restructuring by slashing 61% of its workforce but it was not successful.

This restructuring plan is being done so that Kalobios can pay back its creditors in a timely fashion. Originally Kalobios was ready to forego its operations and find a way to sell itself as it had no more money to continue the pipeline. Although, Martin Shkreli and other hedge fund investors put in about 70% capital to bring money back into the company to continue operations. Everything seemed to be going fine up until the middle of December when Shkreli was arrested by the SEC on fraud charges.

These fraud charges had nothing to do with the new company he invested in, Kalobios. Instead, the charges go way back to when Shkreli was CEO of Retrophin (NASDAQ:RTRX). The charges claim that Shkreli used money from Retrophin to pay off previous hedge fund investors. It would be nice to see the company restructure its business, but it will also face another uphill battle with the NASDAQ stock exchange. This is because the company received a NASDAQ letter stating that it would de-list its shares from the exchange.

Kalobios is now missing a CEO because of his arrest, a few directors leaving, and not much left in the coffers other than a few drugs in early stages of the clinical pipeline. The company posted an appeal to the NASDAQ, in which it is set to be in a hearing in an attempt to keep its shares listed on the NASDAQ exchange. This hearing will take place on February 25, 2016 where panel members will decide upon whether or not shares of Kalobios should continue to be listed on the NASDAQ.

Chimerix, Inc. (NASDAQ:CMRX)

On Monday December 28, 2015 shares of Chimerix fell 80% after the company announced that their drug failed to meet on the primary endpoint, in a phase 3 clinical trial. The phase 3 trial, known as the SUPPRESS trial, recruited up to 452 patients. These patients undergo hematopoietic cell transplants either due too a genetic defect or blood cancer. Because of these cell transplant treatments the patients get Cytamegalovirus or other forms of infection that are similar.

The phase 3 trial was monitoring how well brincidofovir was able to reduce the Cytamegalovirus compared to a placebo compound within a 24-week period. This all occurs after patients have undergone the cell transplant treatment. The company was able to show a reduction of the Cytomegalovirus compared to placebo in the 10-week period, but from week 10 to week 24 the same efficacy was not achieved. To make matters even worse, the brincidofovir group saw an increase in mortality rate which is definitely not good at all.

The results are definitely not great, but the company will still present them at a medical conference which will be held by in February of this year. Although, Chimerix has chosen to axe its hematopoietic cell transplant trial and continue on in other areas. These other areas include smallpox and other adenovirus infections. I will say that the likelihood of efficacious results in these other areas as slim to none, considering that this phase 3 trial failed miserably. If someone is willing to take the risk it might be good for a small gamble, but I wouldn’t get too carried away with it as an investment.

[Image Courtesy of Wikipedia]

Unilife UNIS Stock News

Unilife Corp (NASDAQ: UNIS) | Amgen, Inc. (NASDAQ: AMGN)

Unilife is having an incredible day in the market today after disclosing an SEC filing with regard to an exclusivity agreement with Amgen. The agreement surrounds Unilife’s proprietary technology. Today, we’ll talk about what that technology is, what the agreement entails, how UNIS is reacting in the market, and what we can expect to see from the stock moving forward.

Details Of The UNIS/AMGN Agreement

The agreement between Unilife and Amgen is associated with the companies’ previous announcement with regard to potential strategic alternatives. Under the agreement, UNIS will provide AMGN with the exclusive rights to develop, manufacture, and supply wearable injector devices for use with large volume drug products. The company will also be providing Amgen exclusive rights to develop, manufacture and supply a 1ml wearable injector designed for use with small volume drug products.

In exchange for providing AMGN with the exclusive rights to this technology, UNIS will receive an up-front, non-refundable payment in the amount of $15 million. Amgen has also agreed to purchase up to 19.9% of Unilife’s outstanding common stock. For more details with regard to the agreement, click here.

How The Market Reacted To The News

As investors, we’ve learned that any time we see positive news with regard to a publicly traded company, we can expect to see gains in the value of that company’s stock. That’s exactly what we’re seeing today as a result of the agreement between AMGN and UNIS. Currently (10:08), UNIS is trading at $0.82 per share after a gain of 65.79% so far today. Unfortunately, the same cannot be said for AMGN. As the market continues to react to higher interest rates and worrisome economic conditions around the world, AMGN is following the overall trend downward. Currently, the stock is trading at $157.54 after a loss of 2.95% so far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively bullish opinion of what we can expect to see from UNIS. First and foremost, the new agreement with Amgen offers Unilife the capital it needs for further growth of its operations. Also, under the agreement, we can expect to see a massive purchase of UNIS common stock relatively soon. Naturally, this will send the stock skyrocketing. Moreover, with the support of a well-established biotechnology company, Unilife will have better insight with regard to what it needs to do to achieve growth. All in all, signs are pointing toward positivity in the long run.

In the short run however, it’s important to remember that price movement in the market tends to happen through a series of overreactions. While UNIS gains are warranted to an extent, it’s not likely that this agreement is worth more than 50% growth that will hold up for any substantial period of time. As a result, I’m expecting to see a correction in the stock, bringing the price down to a more sustainable rate before growth continues.

What Do You Think?

Where do you think UNIS is headed moving forward? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Trade With A CNA Finance Trusted Broker
Broker Trade Fees Promotion Sign Up Here





Open a TradeStation Account!

XOMA Corp XOMA Stock News


XOMA is an incredible company that is presenting quite the opportunity at the moment. As time passes, the stock is getting closer and closer to a major catalyst that I believe will send it skyrocketing. It seems as though investors are starting to realize that as well, since short interest surrounding XOMA is currently declining. Today, we’ll talk about what I believe will be a major catalyst for the stock, what we’re seeing with regard to short interest, what we’ve seen from XOMA recently, and what we can expect to see moving forward.

XOMA Will Likely See A Big Catalyst In Early 2016

In the world of biotechnology stocks, there are quite a few events that generally act as catalysts. Clinical trial results, New Drug Application submissions, drug approvals and more all tend to either send a stock skyrocketing or plummeting. Well, one of these events is going to happen with regard to XOMA relatively soon. Earlier in the year, the company produced Phase 2 clinical trial results with regard to XOMA-358, a drug designed to treat patients with hyperinsulinism. The results of the Phase 2 study were overwhelmingly positive. In the study, XOMA-358 proved to be not only safe, but also effective in treating the condition. Now, XOMA is headed for Phase 3, which will likely lead to a New Drug Application in the near future. In a statement, XOMA CEO, Paul Rubin, M.D. had the following to say:

New treatments that safely and effectively attenuate insulin-induced hypoglycemia are needed for patients with congenital hyperinsulinism, as well as other diseases that cause hypoglycemia due to high insulin levels. There are no approved medications, and those that are currently used have inconsistent efficacy and issues with tolerability. Currently disease management options are limited to continuous ingestion or infusion of glucose or surgical removal of part or all of the pancreas… We are developing XOMA 358 as a first-in-class therapeutic for patients with this potentially fatal disease, and we are pleased to be conducting this study at a world-class medical center recognized for its leadership in treating HI patients.”

Soon, the results of the Phase 3 study will become available. Based on the overwhelmingly positive data we’ve seen from both the Phase 1 and Phase 2 trials, I’m expecting for Phase 3 to be positive as well, sending XOMA skyrocketing.

Short Interest Is On The Downtrend

Investors seem to be excited with regard to what they can expect to see from XOMA moving forward as well. Short interest, a key investor sentiment indicator, is declining. From November 30th to December 15th, the number of shares that were being sold short fell from 19,837,207 to 18,874,476.

What We Can Expect To See From XOMA Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from XOMA. Ultimately, this opinion revolves around the positive data that we’ve seen from XOMA 358 and the positivity I’m expecting to see from the Phase 3 trial. As the company’s CEO pointed out, there are no quality treatments currently in place for congenital hyperinsulinism. By creating a treatment, XOMA will enter into an untapped market which will likely lead to incredible profits. With that said, I’m excited to see what’s coming up next with regard to XOMA.

What Do You Think?

Where do you think XOMA is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Trade With A CNA Finance Trusted Broker
Broker Trade Fees Promotion Sign Up Here




Open a TradeStation Account!

Neurometrix NURO Stock News

NeuroMetrix Inc (NASDAQ: NURO)

NeuroMetrix is having an incredible day in the market today after announcing that it has started the commercialization process in Mexico for a detection system known as DPNCheck. Today, we’ll talk about what DPNCheck is, why the launch in Mexico is so important, how NURO is reacting to the news, and what we can expect to see from the stock moving forward.

What Is DPNCheck

DPNCheck by NeuroMetrix is a tool that’s designed to diagnose consumers with diabetes. By measuring sural nerve conduction velocity and response amplitude biomarkers, the test is able to evaluate peripheral neuropathies, most importantly diabetic peripheral neuropathy. The new testing system is not only accurate, but it is incredibly cost effective.

Why Launching In Mexico Is So Important

While Mexico’s population isn’t exactly the largest in the world, it is known to have one of the highest rates of type 2 diabetes in the world. In fact, about 12% of Mexico’s entire adult population has been diagnosed with the condition. The massive amount of consumers with type 2 diabetes is one thing, but the death toll the disease has on the country is astronomical. The reality is that in Mexico, type 2 diabetes is the leading cause of death, resulting in about 70,000 deaths per year. To make matters worse, this figure is expected to rise as the diabetes epidemic continues to grow in the country. Based on this data, it’s clear that Mexico is a great target market for NURO and their DPNCheck program.

As a result of the need, DPNCheck is going to start by being used in one of Mexico’s major government healthcare institutions, of which there are only 6 in the country. Because the largest opportunities for NeuroMetrix are held within these 6 institutions, the largest effort in the commercialization process will be negotiating DPNCheck into all of these institutions down the road, which will be a great thing for NURO.

How The Market Is Reacting To The News

As investors, history has taught us that when positive news comes out with regard to a publicly traded company, we can expect to see a positive reaction in the market as a result. That’s exactly what we saw from NURO as a result of DPNCheck commercialization efforts in Mexico. Currently (10:09), NURO is trading at $2.57 per share after a gain of 11.74% so far today on the news.

What We Can Expect From NURO Moving Forward

Moving forward, I have a relatively bullish opinion of what we can expect to see from NURO. It’s clear that the company is moving things in the right direction in order to lead to long term profits. NURO’s DPNCheck is a much needed diagnostic tool in Mexico and around the world. As the company works to commercialize the tool, chances are that profits will come in a big way. So, if you’re looking for a low cost, emerging biotech company to get involved in, you may want to take a very close look at NURO and the opportunity the stock provides.

What Do You Think?

Where do you think NURO is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Crowd Fund Insider]

Trade With A CNA Finance Trusted Broker
Broker Trade Fees Promotion Sign Up Here




TradeStation$9.99Open a TradeStation Account!

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7802
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...